Influence of smoking cessation drugs on blood pressure and heart rate in patients with cardiovascular disease or high risk score: real life setting

Imagem de Miniatura
Arquivos
art_SILVA_Influence_of_smoking_cessation_drugs_on_blood_pressure_2016.PDF (406.01 KB)
Citações na Scopus
7
Tipo de produção
article
Data de publicação
2016
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
BIOMED CENTRAL LTD
Autores
GAYA, Patricia Viviane
Citação
BMC CARDIOVASCULAR DISORDERS, v.16, article ID 2, 6p, 2016
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: Smoking is the most important reversible cardiovascular risk factor. It is well established that quitting smoking reduces coronary events. However, on several occasions, the cardiovascular safety of smoking cessation drugs has been questioned. Our goal is to evaluate the effects of smoking cessation drugs on blood pressure and heart rate in patients from a smoking cessation service in a cardiology hospital. Methods: We examined the PAF database (Smoking Cessation Assistance Program database) between January 2008 and March 2014. We analyzed data from 900 patients who were compliant with the treatment (50.5 % male, average age 53 +/- 17 years). The most frequent clinical diagnoses were coronary artery disease (25.2 %), hypertension (57.2 %), and diabetes (13.4 %). Blood pressure, heart rate, and carbon monoxide (CO) concentration in exhaled air were analyzed at consecutive visits during the first 45 days of treatment (mean visits - 3). Analysis of repeated measures was used for the statistical analysis (p < 0.05). Results: Two hundred seventy one patients used nicotine replacement therapy (NRT) alone, 81 used bupropion alone, 154 used varenicline alone, 283 used NRT plus bupropion and 111 used bupropion plus varenicline. For all smoking cessation drugs, used alone or in combination, no increase occurred in the average value of systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart rate (HR). Significant reductions in CO concentrations occurred in all smoking cessation drug groups. Conclusion: Smoking cessation drugs used in monotherapy or in combined regimens did not influence systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart rate (HR) in this group of patients during the observation period.
Palavras-chave
Smoking cessation, Nicotine replacement therapy, Bupropion, Varenicline, Cardiovascular disease, Hypertension
URI
https://observatorio.fm.usp.br/handle/OPI/12884
Referências
  1. DACOSTA A, 1993, EUR HEART J, V14, P1709
  2. Issa JS, 2011, TOB CONTROL, V20, P156, DOI 10.1136/tc.2010.037614
  3. Tanus-Santos JE, 2001, AM J HYPERTENS, V14, P610, DOI 10.1016/S0895-7061(01)01301-2
  4. Issa JS, 2013, NICOTINE TOB RES, V15, P1146, DOI 10.1093/ntr/nts230
  5. Sobieraj DM, 2013, J AM SOC HYPERTENS, V7, P61, DOI 10.1016/j.jash.2012.11.003
  6. FAGERSTROM KO, 1989, J BEHAV MED, V12, P159, DOI 10.1007/BF00846549
  7. Najem B, 2006, HYPERTENSION, V47, P1162, DOI 10.1161/01.HYP.0000219284.47970.34
  8. ROOSE SP, 1991, AM J PSYCHIAT, V148, P512
  9. Tonstad S, 2003, EUR HEART J, V24, P946, DOI 10.1016/S0195-668X(03)00003-4
  10. Settle EC, 1999, CLIN THER, V21, P454, DOI 10.1016/S0149-2918(00)88301-0
  11. Mills EJ, 2014, CIRCULATION, V129, P28, DOI 10.1161/CIRCULATIONAHA.113.003961
  12. Thase ME, 2008, J CLIN PSYCHOPHARM, V28, P302, DOI 10.1097/JCP.0b013e318172424e
  13. Jha P, 2013, NEW ENGL J MED, V368, P341, DOI 10.1056/NEJMsa1211128
  14. Glantz S, 2012, LANCET, V379, P1269, DOI 10.1016/S0140-6736(11)60615-6
  15. Eisenberg MJ, 2013, J AM COLL CARDIOL, V61, P524, DOI 10.1016/j.jacc.2012.08.1030
  16. Issa JS, 2012, J BRAS PNEUMOL, V38, P761, DOI 10.1590/S1806-37132012000600012
  17. Tonstad S, 2006, JAMA-J AM MED ASSOC, V296, P64, DOI 10.1001/jama.296.1.64
  18. Zevin S, 1998, CLIN PHARMACOL THER, V64, P87, DOI 10.1016/S0009-9236(98)90026-1
  19. Singh S, 2011, CAN MED ASSOC J, V183, P1359, DOI 10.1503/cmaj.110218
  20. Rigotti NA, 2010, CIRCULATION, V121, P221, DOI 10.1161/CIRCULATIONAHA.109.869008
  21. Rigotti NA, 2006, AM J MED, V119, P1080, DOI 10.1016/j.amjmed.2006.04.024
  22. Ebbert JO, 2014, JAMA-J AM MED ASSOC, V311, P155, DOI 10.1001/jama.2013.283185
  23. Fiore MC, 2008, TREATING TOBACCO USE
  24. Mills Edward J, 2010, Tob Induc Dis, V8, P8, DOI 10.1186/1617-9625-8-8
  25. Prochaska JJ, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e2856
  26. Roose S P, 2000, Am Heart J, V140, P84, DOI 10.1067/mhj.2000.109977
  27. Rose JE, 2014, AM J PSYCHIAT, V171, P1199, DOI 10.1176/appi.ajp.2014.13050595
  28. Yugar-Toledo Juan Carlos, 2005, J Clin Hypertens (Greenwich), V7, P721, DOI 10.1111/j.1524-6175.2005.04597.x

Coleções
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - LIM/13
Artigos e Materiais de Revistas Científicas - ODS/03